Navigation Links
Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007
Date:11/1/2007

WALTHAM, Mass., Nov. 1 /PRNewswire/ -- Proteon Therapeutics (http://www.proteontherapeutics.com), a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, is presenting tomorrow at the Annual Meeting of the American Society of Nephrology an abstract entitled "Recombinant Human Elastase (PRT-201) Dilates Outflow Veins in a Preclinical Model of Arteriovenous Fistula." Findings to be presented represent an important preclinical demonstration of the potential of PRT-201 to enhance arteriovenous fistula (AVF) surgery outcomes in patients requiring chronic hemodialysis. It is well documented that between 30 and 50 percent of AVFs, the preferred form of vascular access, fail to mature to usable access sites for dialysis patients.

"Vascular access related complications are a major cause of suffering and hospitalization for dialysis patients," said Timothy P. Noyes, the Company's President and CEO. "We believe that PRT-201 could potentially facilitate the creation of more reliable dialysis access sites."

About Vascular Access in Hemodialysis

Patients with end stage kidney disease must undergo periodic external blood filtering by hemodialysis machines in order to remove fluid and metabolic byproducts from their blood. Vascular surgeons prepare patients for hemodialysis by creating access sites in the body that can be connected to hemodialysis machines. These high flow access sites are usually created by connecting an artery to a vein, resulting in a "shunt" of blood from the artery to the vein. There are three main types of chronic hemodialysis access sites: Arteriovenous fistulas are created by connecting veins directly to arteries, arteriovenous grafts are created by connecting veins to arteries with a segment of artificial tubing, and catheters are placed directly in large veins in the neck or chest. These access sites are often difficult to create and prone to failure, resulting in treatment interruptions, hospitalizations, painful corrective surgical procedures, and premature death.

About Proteon Therapeutics

Proteon Therapeutics, Inc. is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical, rapidly expanding medical needs of patients with kidney and vascular diseases. The company is leveraging a unique understanding of tissue remodeling to develop a pipeline of proprietary pharmaceuticals. The company is headquartered in Waltham, MA, and has research facilities in Kansas City, MO. For additional information please visit http://www.proteontherapeutics.com.


'/>"/>
SOURCE Proteon Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
3. Wisconsin firms to present at Cleantech venture capital event
4. New Sonic Foundry search engine finds words, phrases in video presentations
5. Lone Wisconsin firm to present at InvestMidwest
6. Sonic Foundry creates search engine for 7,000 expert video presentations
7. InvestMidWest calls for business presentations
8. Wicab to present BrainPort at Boston conference
9. Three more Wisconsin firms to present at venture forum
10. Six Wisconsin firms to present at BIO Mid-America VentureForum
11. New Health and Human Services representative for Midwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... ... October 06, 2017 , ... ... launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available ... bioinformatics software to perform Hi-C metagenome deconvolution using their own facilities, supplementing ...
(Date:10/6/2017)... ... October 06, 2017 , ... The HealthTech ... technology sector at their fourth annual Conference where founders, investors, innovative practitioners and ... the ELEVATE pitch competition showcasing early stage digital health and med tech companies. ...
(Date:10/5/2017)... , ... October 05, 2017 , ... LabRoots , ... scientists from around the world, is giving back to cancer research with a month-long ... , Now through October 31, shoppers can use promo code PinkRibbon to get ...
(Date:10/5/2017)... Baltimore, MD (PRWEB) , ... October 05, 2017 ... ... over $1.7M to develop new applications of its Nanobind DNA/RNA extraction technology ... micro- and nanostructured silica on the surface and that can be used for ...
Breaking Biology Technology:
(Date:4/17/2017)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... 2016 Annual Report on Form 10-K on Thursday April 13, 2017 ... ... Investor Relations section of the Company,s website at http://www.nxt-id.com  under ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... , April 11, 2017 No ... but researchers at the New York University Tandon ... of Engineering have found that partial similarities between ... systems used in mobile phones and other electronic ... The vulnerability lies in the fact ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
Breaking Biology News(10 mins):